- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04082364
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)
A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.
Part A is a single-arm cohort (Cohort A, 40 to 110 patients) will evaluate safety and efficacy of margetuximab plus retifanlimab.
Part B has 2 subparts. Cohort B1 has 4 arms (50 patients/arm). Patients will be randomized to margetuximab plus retifanlimab plus chemotherapy, margetuximab plus tebotelimab, plus chemotherapy, margetuximab plus chemotherapy, or trastuzumab plus chemotherapy. The most effective combination with margetuximab from Cohort B1 will be used in Cohort B2.
Cohort B2 has 2 arms (250 patients/arm). Patients will be randomized to margetuximab plus retifanlimab or tebotelimab plus chemotherapy, or to trastuzumab plus chemotherapy.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Changchun, China, 130000
- Jilin Cancer Hospital (Second People's Hospital Of Jilin Province)
-
Fuzhou, China, 350005
- Fujian Medical University - Fujian Provincial Cancer Hospital (Fujian Provincial Tumor Hospital)
-
Hangzhou, China, 310016
- Sir Run Run Shaw Hospital, Zhejiang University School Of Medicine
-
Hangzhou, China, 310022
- Zhejiang Cancer Hospital
-
Harbin, China, 150081
- Affiliated Tumor Hospital of Harbin Medical University- the 3rd Affiliated Hospital of Harbin
-
Hefei, China, 230022
- The First affiliated Hospital of Anhui Medical University
-
Hefei, China, 230031
- Anhui Provincial Cancer Hospital
-
Jinan, China, 250013
- Jinan Center Hospital
-
Nanjing, China, 210000
- Nanjing University Medical School; Nanjing Drug Tower
-
Shanghai, China, 200433
- Zhongshan Hospital Fudan University
-
Shenyang, China, 110042
- Liaoning cancer hospital
-
Shijiazhuang, China, 050000
- Hebei cancer hospital (The Fourth Affiliate)
-
Wuhan, China, 430022
- Wuhan Union Hospital
-
Zhengzhou, China, 450008
- Henan Cancer Hospital
-
Zhenzhou, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
-
-
-
-
Frankfurt, Germany, 60488
- Institute of Clinical Cancer Research Krankenhaus Nordwest (IKF)
-
Hamburg, Germany
- Haematologisch-Onkologische Praxis Eppendorf
-
Mainz, Germany
- Universitätsmedizin Mainz
-
Monchengladbach, Germany
- Kliniken Maria Hilf GmbH
-
-
-
-
-
Milan, Italy, 20132
- Ospedale San Raffaele
-
Milan, Italy
- Istituto Europeo di Oncologia
-
Pisa, Italy, 56126
- Azienda Ospedaliero-Universitaria Pisana
-
-
-
-
-
Anyang-Si, Korea, Republic of, 14068
- Hallym University Sacred Heart Hospital
-
Gyeonggi-do, Korea, Republic of
- CHA bundang
-
Haeundae, Korea, Republic of
- Inje University Haeundae Paik Hospital
-
Seongnam-si, Korea, Republic of
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Korea University Guro
-
Seoul, Korea, Republic of
- Korea University, Anam Hospital
-
Seoul, Korea, Republic of
- Yonsei University College of Medicine (Severance Hospital)
-
Suwon, Korea, Republic of
- Catholic University of Korea St. Vincent Hospital
-
-
-
-
-
Lublin, Poland, 20-081
- SPSK nr 1 in Lublin
-
Rzeszów, Poland, 35-922
- Centrum Medyczne MrukMed
-
-
-
-
-
Singapore, Singapore, 169610
- National Cancer Center Singapore
-
Singapore, Singapore, 119074
- National University Hospital (Cancer Institute) -Singapore
-
-
-
-
-
Kaohsiung, Taiwan, 83301
- Kaohsiung Chang Gung MemorialHospital
-
Keelung, Taiwan, 204
- Chang Gung Memorial Hospital, Keelung
-
Tainan city, Taiwan, 73657
- Liuying Chi MeiMedical Hospital
-
Taipei, Taiwan
- National Taiwan University
-
-
Taipei
-
Taipei City, Taipei, Taiwan, 110
- Taipei Medical University Hospital
-
-
-
-
-
Cambridge, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital
-
Manchester, United Kingdom
- The Christie Hospital NHS Foundation Trust
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic - Scottsdale
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Comprehensive Cancer Center - Duarte
-
Los Angeles, California, United States, 90033
- Norris Comprehensive Cancer Center (USC)
-
Salinas, California, United States, 93901
- Salinas Memorial
-
Santa Monica, California, United States, 90404
- UCLA School of Medicine
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Yale University
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Florida Cancer Specialists South
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic - Jacksonville
-
Ocala, Florida, United States, 34474
- Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala
-
Saint Petersburg, Florida, United States, 33705
- Florida Cancer Specialists NORTH
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96814
- Kaiser Permanente
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University Of Chicago
-
Skokie, Illinois, United States, 60076
- Edward H. Kaplan MD & Associates
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
Grand Rapids, Michigan, United States, 49503
- Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic - Rochester
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- Nebraska Heme Onc
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- The University of New Mexico Comprehensive Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Stephenson Cancer Center at OUHSC
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- Oncology Consultants
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Utah Cancer Specialists
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Cancer Institute
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
Histologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic HER2+ GC or GEJ adenocarcinoma
- Prior systemic perioperative treatment is allowed; however the patient must have had a disease-free interval of at least 6 months from end of chemo/surgery
- Patients receiving perioperative anti-HER2 therapy require testing of HER2 status for eligibility
- Cohort A: HER2-positive (by IHC 3+) and PD-L1-positive (by IHC with 22C3 CPS ≥ 1%) per central review
- Cohort B: HER2-positive (by IHC 3+ or IHC 2+ in combination with FISH+) by local review. PD -L1 status is not required for enrollment.
- Availability of formalin-fixed, paraffin-embedded tumor specimen, unstained slides or contemporaneous biopsy for tumor target testing
- Eastern Cooperative Oncology Group performance status of 0 or 1, verified within 3 days of Day 1
- Life expectancy ≥ 6 months
- At least one radiographically measurable target lesion
- Acceptable laboratory parameters and adequate organ function
Key Exclusion Criteria:
Other malignancy that is progressing or required treatment within the past 5 years, with certain exceptions
- Patients with known MSI-H status
- History of allogeneic stem cell or tissue/solid organ transplant
- Central nervous system metastases
Clinically significant cardiovascular disease, gastrointestinal disorders, pulmonary compromise
- Prior neoadjuvant or adjuvant treatment with immunotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chemotherapy-free arm
margetuximab plus retifanlimab
|
margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
Other Names:
Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
Other Names:
|
Experimental: Margetuximab, retifanlimab, and chemotherapy arm
margetuximab plus retifanlimab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6) |
margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
Other Names:
Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
Other Names:
Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6 Chemotherapy XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion. |
Experimental: Margetuximab, tebotelimab and chemotherapy arm
margetuximab plus tebotelimab plus investigator choice of chemotherapy options.
Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
|
margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
Other Names:
Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6 Chemotherapy XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion.
Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.
Other Names:
|
Experimental: Margetuximab and chemotherapy arm
margetuximab plus investigator choice of chemotherapy options.
Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
|
margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
Other Names:
Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6 Chemotherapy XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion. |
Active Comparator: Trastuzumab and chemotherapy arm
Trastuzumab plus investigator choice of chemotherapy options.
Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
|
Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6 Chemotherapy XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion.
Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events of margetuximab plus retifanlimab as assessed by CTCAE v5.0
Time Frame: Throughout the study up to 24 months
|
Evaluation of adverse events and serious adverse events (Cohort A)
|
Throughout the study up to 24 months
|
Objective response rate (ORR) for non-microsatellite instability-high (non-MSI-H) patients (Cohort A)
Time Frame: Throughout the study up to 24 months
|
Proportion of non MSI-H patients with best overall response of complete response (CR) plus partial response (PR) per RECIST 1.1 (Cohorts A )
|
Throughout the study up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: Up to 3 years
|
Time from start of study treatment to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.
(Cohorts A)
|
Up to 3 years
|
Duration of response
Time Frame: Up to 3 years
|
Time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first (Cohorts A)
|
Up to 3 years
|
Disease control rate
Time Frame: Up to 3 years
|
Percentage of patients who experienced response of CR, PR or stable disease for at least 3 months from start of study treatment (Cohorts A and B)
|
Up to 3 years
|
ORR for Cohort B
Time Frame: Throughout study participation, up to 24 months.
|
Proportion of non-MSI-high patients iwth best overall response of CR plus PR per RECIST 1.1
|
Throughout study participation, up to 24 months.
|
Number of patients who have antidrug antibodies (ADA) to margetuximab
Time Frame: Throughout study participation, up to 24 months.
|
Throughout study participation, up to 24 months.
|
|
Number of patients who have ADA to retifanlimab
Time Frame: Throughout study participation, up to 24 months.
|
Throughout study participation, up to 24 months.
|
|
Number of patients who have ADA to tebotelimab
Time Frame: Throughout study participation, up to 24 months.
|
Throughout study participation, up to 24 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Stephen L. Eck, MD, PhD, MacroGenics
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-MGAH22-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on margetuximab
-
Zai Lab (Shanghai) Co., Ltd.CompletedHER2 Positive Metastatic Breast CancerChina
-
MacroGenicsNational Cancer Institute (NCI); Green Cross CorporationCompletedBreast Cancer | Gastric CancerKorea, Republic of, United States
-
MacroGenicsMerck Sharp & Dohme LLCCompletedStomach Cancer | Gastric Cancer | Esophageal CancerKorea, Republic of, United States, Taiwan, Singapore, Canada
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
MacroGenicsCompleted
-
MacroGenicsCompletedCervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid TumorsHong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
-
MacroGenicsCompletedHER-2 Positive Breast Cancer | Metastatic NeoplasmUnited States, Spain, Italy, Canada, Israel, Belgium, Germany, Czechia, Austria, Korea, Republic of, Denmark, United Kingdom, Portugal, France, Poland, Netherlands, Finland, Puerto Rico
-
MedSIRMacroGenics; Seagen Inc.WithdrawnAdvanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
-
Dana-Farber Cancer InstituteMacroGenics; Translational Breast Cancer Research ConsortiumRecruitingBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage III Breast CancerUnited States
-
Zai Lab (Shanghai) Co., Ltd.Active, not recruiting